The Lead Discovery Center (LDC), Max Planck Innovation and SOTIO have signed a collaboration and licence agreement providing SOTIO with exclusive rights to an oncology programme addressing a novel target in tumour metabolism.
Collaboration
Under the terms of this agreement, LDC and its academic partners will perform further lead optimisation and identify corresponding biomarkers for the programme in collaboration with SOTIO. Once a pre-clinical candidate has been nominated, SOTIO will take on the responsibility for the preclinical and clinical development as well as subsequent marketing and commercialisation.
“We are excited to collaborate with SOTIO,” said Dr Bert Klebl, CEO of LDC. “The team at SOTIO combines strong, global development expertise with the dynamic spirit of a mid-sized innovation leader. This makes them an ideal partner for translating the results of our collaborative efforts with the Max Planck team into novel therapies. Together we have investigated and developed a completely new molecular mechanism for the potential future therapy of cancer patients. With SOTIO on board, we are perfectly positioned to progress this new drug candidate to patients as fast as possible.”
“Targeting cancer metabolism is a highly attractive and innovative approach for the treatment of cancer. Based on the world-class research at Max Planck, the team at LDC has generated very interesting lead candidates on this first-in-class cancer metabolism programme with a promising safety and efficacy profile,” added Ladislav Bartonicek, CEO of SOTIO.